U.S. flag An official website of the United States government
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Sooil Development Co., Ltd. - 607127 - 02/21/2023
  1. Warning Letters

CLOSEOUT LETTER

Sooil Development Co., Ltd. MARCS-CMS 607127 —

Product:
Medical Devices

Recipient:
Recipient Name
Jin-Seok Noh
Recipient Title
General Manager of Quality Assurance
Sooil Development Co., Ltd.

Yongin-si
Gyeonggi-do
16922
South Korea

yoonheey@sooil.com
Issuing Office:
Center for Devices and Radiological Health

United States


Dear Jin-Seok Noh:

The Food and Drug Administration has completed an evaluation of your firm’s corrective actions in response to our Warning Letter (CMS # 607127, dated April 16, 2020). Based on our evaluation, it appears that you have addressed the violation(s) contained in this Warning Letter. Feedback related to the November 28 through December 1, 2022, was provided to you via email on February 9, 2023, Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.

This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.


Sincerely,
/S/
Marianela Perez-Torres, Ph.D.
Acting Director
Division of Chemistry and Toxicology Devices
OHT7: Office of In Vitro Diagnostics
Office of Product Evaluation and Quality
Center for Devices and Radiological Health

CC:
Jong Hyun Kim
SOOIL LLC
Jeremy@sooilusa.com

 
Back to Top